M. Touya

发表

Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.

M. Broder, E. Chang, M. Greene, 2018, Clinical therapeutics.

Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder

M. Broder, E. Chang, M. Greene, 2018, Journal of medical economics.

A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States

M. Greene, A. Guérin, M. Cloutier, 2018, Journal of medical economics.

Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.

M. Broder, E. Chang, M. Greene, 2018, Journal of comparative effectiveness research.

All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics

M. Broder, E. Chang, M. Greene, 2018, Current medical research and opinion.

Characterizing Primary Care for Patients With Major Depressive Disorder Using Electronic Health Records of a US-Based Healthcare Provider.

M. Gionfriddo, M. Touya, Sharon Larson, 2021, Journal of affective disorders.

Choice of ICD‐10 codes for the identification of acute coronary syndrome in the French hospitalization database

A. Pariente, N. Moore, P. Girodet, 2015, Fundamental & clinical pharmacology.

Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis

M. Touya, M. Polson, A. Kangethe, 2021, BMC Health Services Research.

Results and validation of an index to measure health state of patients with depression in automated healthcare databases

C. Lançon, P. Llorca, P. Verpillat, 2019, Journal of market access & health policy.

Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program

J. Manjelievskaia, M. Touya, M. McCue, 2021, Current medical research and opinion.

Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data

M. Touya, M. Polson, A. Kangethe, 2022, BMC Psychiatry.

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study

J. Haro, B. Rive, M. Knapp, 2017, Neuropsychiatric disease and treatment.

The economic burden of bipolar I disorder in the United States in 2015.

E. Wu, M. Greene, A. Guérin, 2018, Journal of affective disorders.

Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study

B. Baune, A. Ettrup, Bjarke Ebert, 2021, Neuropsychiatric disease and treatment.

Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA

M. Greene, O. Clark, M. Touya, 2018, Neuropsychiatric disease and treatment.

Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study

J. Sarkar, M. Touya, Subina Surendran, 2022, Current medical research and opinion.

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study

J. Haro, B. Rive, D. Saragoussi, 2018, Neuropsychiatric disease and treatment.

Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

M. Broder, E. Chang, M. Greene, 2018, Advances in Therapy.

Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant

L. Ereshefsky, C. François, N. Danchenko, 2020, Expert review of pharmacoeconomics & outcomes research.

Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder.

M. Broder, E. Chang, M. Greene, 2019, Journal of comparative effectiveness research.

The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data

L. Citrome, S. Bhattacharjee, R. Stellhorn, 2023, Journal of medical economics.

Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases

C. Lançon, P. Llorca, B. Falissard, 2019, Journal of market access & health policy.

Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.

M. Greene, Margarida Augusto, M. Touya, 2018, Journal of comparative effectiveness research.

Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type i in the USA

M. Greene, O. Clark, M. Touya, 2018 .

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study

J. Haro, B. Rive, D. Saragoussi, 2018, Neuropsychiatric disease and treatment.

Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.

M. Greene, Margarida Augusto, M. Touya, 2018, Journal of comparative effectiveness research.

Antidepressant Use and Treatment-Emergent Sexual Dysfunction Among Patients With Major Depressive Disorder: Results From an Internet-Based Survey Study

M. Touya, L. Chrones, Judith J. Stephenson, 2024, Journal of Affective Disorders Reports.